Literature DB >> 18722263

Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose.

Louis S Constine1, Nancy Tarbell, Melissa M Hudson, Cindy Schwartz, Susan G Fisher, Ann G Muhs, Swati K Basu, Larry E Kun, Andrea Ng, Peter Mauch, Ajay Sandhu, Eva Culakova, Gary Lyman, Nancy Mendenhall.   

Abstract

PURPOSE: Subsequent malignant neoplasms (SMNs) are a dominant cause of morbidity and mortality in children treated for Hodgkin's disease (HD). We evaluated select demographic and therapeutic factors associated with SMNs, specifically gender and radiation dose. METHODS AND MATERIALS: A total of 930 children treated for HD at five institutions between 1960 and 1990 were studied. Mean age at diagnosis was 13.6 years, and mean follow-up was 16.8 years (maximum, 39.4 years). Treatment included radiation alone (43%), chemotherapy alone (9%), or both (48%).
RESULTS: We found that SMNs occurred in 102 (11%) patients, with a 25-year actuarial rate of 19%. With 15,154 patient years of follow-up, only 7.18 cancers were expected (standardized incidence ratio [SIR] = 14.2; absolute excess risk [AER] = 63 cases/10,000 years). The SIR for female subjects, 19.93, was significantly greater than for males, 8.41 (p < 0.0001). After excluding breast cancer, the SIR for female patients was 15.4, still significantly greater than for male patients (p = 0.0012). Increasing radiation dose was associated with an increasing SIR (p = 0.0085). On univariate analysis, an increased risk was associated with female gender, increasing radiation dose, and age at treatment (12-16 years). Using logistic regression, mantle radiation dose increased risk, and this was 2.5-fold for female patients treated with more than 35 Gy primarily because of breast cancer.
CONCLUSIONS: Survivors of childhood HD are at risk for SMNs, and this risk is greater for female individuals even after accounting for breast cancer. Although SMNs occur in the absence of radiation therapy, the risk increases with RT dose.

Entities:  

Mesh:

Year:  2008        PMID: 18722263      PMCID: PMC3531236          DOI: 10.1016/j.ijrobp.2008.04.067

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  53 in total

1.  Risk of second cancers after treatment for Hodgkin's disease.

Authors:  M A Tucker; C N Coleman; R S Cox; A Varghese; S A Rosenberg
Journal:  N Engl J Med       Date:  1988-01-14       Impact factor: 91.245

2.  Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease.

Authors:  S S Donaldson; M P Link
Journal:  J Clin Oncol       Date:  1987-05       Impact factor: 44.544

3.  Leukemia following Hodgkin's disease.

Authors:  J M Kaldor; N E Day; E A Clarke; F E Van Leeuwen; M Henry-Amar; M V Fiorentino; J Bell; D Pedersen; P Band; D Assouline
Journal:  N Engl J Med       Date:  1990-01-04       Impact factor: 91.245

4.  Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial.

Authors:  U Rühl; M Albrecht; K Dieckmann; H Lüders; H Marciniak; D Schellenberg; L Wickmann; W Dörffel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-12-01       Impact factor: 7.038

5.  Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger.

Authors:  Andrea K Ng; M Patricia Bernardo; Edie Weller; Kendall H Backstrand; Barbara Silver; Karen C Marcus; Nancy J Tarbell; Jonathan Friedberg; George P Canellos; Peter M Mauch
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

6.  Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease.

Authors:  Lois B Travis; Mary Gospodarowicz; Rochelle E Curtis; E Aileen Clarke; Michael Andersson; Bengt Glimelius; Timo Joensuu; Charles F Lynch; Flora E van Leeuwen; Eric Holowaty; Hans Storm; Ingrid Glimelius; Eero Pukkala; Marilyn Stovall; Joseph F Fraumeni; John D Boice; Ethel Gilbert
Journal:  J Natl Cancer Inst       Date:  2002-02-06       Impact factor: 13.506

7.  Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years.

Authors:  Graça M Dores; Catherine Metayer; Rochelle E Curtis; Charles F Lynch; E Aileen Clarke; Bengt Glimelius; Hans Storm; Eero Pukkala; Flora E van Leeuwen; Eric J Holowaty; Michael Andersson; Tom Wiklund; Timo Joensuu; Mars B van't Veer; Marilyn Stovall; Mary Gospodarowicz; Lois B Travis
Journal:  J Clin Oncol       Date:  2002-08-15       Impact factor: 44.544

8.  Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors.

Authors:  Andrea K Ng; M V Patricia Bernardo; Edie Weller; Kendall Backstrand; Barbara Silver; Karen C Marcus; Nancy J Tarbell; Mary Ann Stevenson; Jonathan W Friedberg; Peter M Mauch
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

9.  VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial.

Authors:  Sarah S Donaldson; Melissa M Hudson; Kathleen R Lamborn; Michael P Link; Larry Kun; Amy Louise Billett; Karen C Marcus; Craig A Hurwitz; Jeffrey A Young; Nancy J Tarbell; Howard J Weinstein
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544

10.  Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries.

Authors:  J M Kaldor; N E Day; P Band; N W Choi; E A Clarke; M P Coleman; M Hakama; M Koch; F Langmark; F E Neal
Journal:  Int J Cancer       Date:  1987-05-15       Impact factor: 7.396

View more
  38 in total

1.  Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.

Authors:  Jean L Nakamura; Connie Phong; Emile Pinarbasi; Scott C Kogan; Scott Vandenberg; Andrew E Horvai; Bruce A Faddegon; Dorothea Fiedler; Kevan Shokat; Benjamin T Houseman; Richard Chao; Russell O Pieper; Kevin Shannon
Journal:  Cancer Res       Date:  2011-01-01       Impact factor: 12.701

2.  Inconsistent mammography perceptions and practices among women at risk of breast cancer following a pediatric malignancy: a report from the Childhood Cancer Survivor Study.

Authors:  Stephanie M Smith; Jennifer S Ford; William Rakowski; Chaya S Moskowitz; Lisa Diller; Melissa M Hudson; Ann C Mertens; Annette L Stanton; Tara O Henderson; Wendy M Leisenring; Leslie L Robison; Kevin C Oeffinger
Journal:  Cancer Causes Control       Date:  2010-05-27       Impact factor: 2.506

Review 3.  Secondary malignancies across the age spectrum.

Authors:  Andrea K Ng; Lisa B Kenney; Ethel S Gilbert; Lois B Travis
Journal:  Semin Radiat Oncol       Date:  2010-01       Impact factor: 5.934

4.  Breast cancer after chest radiation therapy for childhood cancer.

Authors:  Chaya S Moskowitz; Joanne F Chou; Suzanne L Wolden; Jonine L Bernstein; Jyoti Malhotra; Danielle Novetsky Friedman; Nidha Z Mubdi; Wendy M Leisenring; Marilyn Stovall; Sue Hammond; Susan A Smith; Tara O Henderson; John D Boice; Melissa M Hudson; Lisa R Diller; Smita Bhatia; Lisa B Kenney; Joseph P Neglia; Colin B Begg; Leslie L Robison; Kevin C Oeffinger
Journal:  J Clin Oncol       Date:  2014-04-21       Impact factor: 44.544

5.  Secondary Malignancies Following Treatment for Hodgkin's Lymphoma in Childhood and Adolescence.

Authors:  Wolfgang Dörffel; Marianne Riepenhausenl; Heike Lüders; Jürgen Brämswig; Günther Schellong
Journal:  Dtsch Arztebl Int       Date:  2015-05-01       Impact factor: 5.594

6.  Breast cancer surveillance in patients treated by radiotherapy for Hodgkin's lymphoma.

Authors:  G Mariscotti; M Durando; G Ghione; A Luparia; E Regini; C Alfieri; P P Campanino; P Gavarotti; E Brignardello; G Gandini
Journal:  Radiol Med       Date:  2012-08-08       Impact factor: 3.469

7.  Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031.

Authors:  Debra L Friedman; Lu Chen; Suzanne Wolden; Allen Buxton; Kathleen McCarten; Thomas J FitzGerald; Sandra Kessel; Pedro A De Alarcon; Allen R Chen; Nathan Kobrinsky; Peter Ehrlich; Robert E Hutchison; Louis S Constine; Cindy L Schwartz
Journal:  J Clin Oncol       Date:  2014-10-13       Impact factor: 44.544

8.  Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children's Oncology Group.

Authors:  Burton E Appel; Lu Chen; Allen Buxton; Suzanne L Wolden; David C Hodgson; James B Nachman
Journal:  Pediatr Blood Cancer       Date:  2012-07-27       Impact factor: 3.167

9.  Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.

Authors:  Grace Choi; Brian Huang; Emile Pinarbasi; Steve E Braunstein; Andrew E Horvai; Scott Kogan; Smita Bhatia; Bruce Faddegon; Jean L Nakamura
Journal:  Cancer Res       Date:  2012-10-15       Impact factor: 12.701

10.  [Radiotherapy in the treatment of advanced and recurrent prostate cancer].

Authors:  D Böhmer
Journal:  Urologe A       Date:  2012-12       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.